Excess body weight is a leading cause of metabolic complications such as hypertension and dyslipidemia in T2DM patients. Available antihyperglycemic agents have minimal or no impact on these complications and a majority are known to trigger weight gain, thereby exerting a paradoxical effect on overall metabolic status. This review introduces the concept of 'KgA1c paradox' and underscores the significance of resolving this paradox for comprehensive T2DM management. It provides a therapeutic rationale for inclusion of sodium glucose cotransporter 2 inhibitors in the T2DM treatment algorithm as these agents have demonstrated favorable glycemic effects along with reduction in body weight.
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; KgA1c paradox; Overweight; SGLT2 inhibitors; Type 2 diabetes mellitus.
Copyright © 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.